China Medical Technologies | GenomeWeb

China Medical Technologies

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Investors are suing China Medical Technologies alleging the firm engaged in actions that artificially inflated its stock in violation of US securities law.

Beijing-based China Medical Technologies said this week that China's State Food and Drug Administration has approved its real-time PCR-based KRAS assay as a companion diagnostic test for the use of a targeted colorectal cancer drug.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – China Medical Technologies today announced that its PCR-based KRAS assay has been approved in China as a companion diagnostic for an undisclosed drug targeting colorectal cancer.

China Medical Technologies' wholly owned subsidiary Beijing GP Medical Technologies and Da An Health will co-market and promote molecular diagnostic products to hospitals in China.

Sales of its FISH probes and new HPV-DNA chips helped drive up sales in its molecular diagnostics systems segment.

Gen-Probe launches Elucigene KRAS.BRAF kit; China Medical Technologies gets Chinese approval for EGFR assay.

The firm said that its test is the first PCR-based EGFR assay approved by the State Food and Drug Administration of China.

According to the firm, its chip can detect high risk and low risk genotypes, distinguish multiple HPV infections, and determine the viral load.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.